Clay Siegall’s Glowing Achievements in the Field of Oncology

Dr. Clay Siegall, Ph.D., is the President, CEO and Board Chairman of Seattle Genetics. According to Seattlegenetics.com, Siegall established the firm in 1998 on a strong scientific, research and drug development platform. Siegall has been instrumental in overseeing several groundbreaking studies, including the development of ADCs or antibody drug conjugates. One of the most successful, internationally acclaimed ADC products from the company is ADCETRIS (brentumixmab vedotin), which has been prescribed to fight lymphomas. The brand is now available in over 60 countries around the world. Under the guidance of Dr. Siegall, the firm has also signed several strategic licenses with world leading drug makers such as Pfizer, GlaxoSmithKline and Roche.

The strategic partnerships signed by Seattle Genetics for its flagship ADC drugs have generated over $320 million. Dr. Siegall has also been instrumental in spearheaded various fundraising ventures to raise capital for various research initiatives. The company has so far raised over $2 billion from its 2001 IPO and contributions from private and public donors. Prior to establishing Seattle Genetics, Dr. Clay Siegall worked at various internationally recognized research organizations. According to an overview published by Crunchbase, Dr. Siegall served at the National Cancer Institute (NCI), National Institutes of Health for duration of 3 years from 1988 to 1991. He later moved to Bristol-Myers Squibb Pharmaceuticals Research Institute to work as lead researcher from 1991 to 1997.

A quick look at various publications, blogs and online reviews reveals many positive things about Dr. Siegall and his company. According to the Human Daddy blog, Glass Door paints Seattle Genetics as having a great campus and a productive, small company feel. Dr. Siegall and Seattle Genetics have also received admirable reviews from the Forbes and Hackronym.com blogs. Dr Siegall got involved in the front lines of fighting cancer research after his late father was diagnosed with brain cancer. He studied for his Bachelor’s of Science degree in Zoology at the University of Maryland, before advancing for his PhD in Genetics at George Washington University. To cap his roll of achievements, Dr. Siegall holds 15 patents and over 70 publications to his credit.